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ABSTRACT
ROLE OF HDACS AND SAM IN INTERFERON-ALPHA SIGNALING AND
EPIGENETIC REGULATION OF ANTI-HCV GENE EXPRESSION

Stephanie A. Mathews
November 28,2011

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease in the
United States and is a huge burden on the US healthcare system. The FDAapproved traditional standard of care for HCV is pegylated interferon-alpha
(lFNa) combined with ribavirin, which is effective in about 50% of patients. The
molecular mechanisms involved in resistance to IFNa therapy remain unclear.
Recent data strongly suggest that histone deacetylases (HDACs) and
methylation play critical roles in the regulation of IFNa anti-HCV signaling and
gene expression. The present work was carried out to elucidate the roles of
HDACs and S-adenosylmethionine (SAM) metabolism in regulating IFNa antiHCV signaling in human hepatoma cells.

Inhibition of HDACs, by pharmacologic HDAC inhibitors or siRNA, significantly
suppressed IFNa-mediated antiviral gene expression and partially reversed the
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anti-HCV action of IFNa in human hepatoma cells. The decrease in antiviral
gene expression correlated with decreased retention time of activated STATs in
the nucleus, an increase in STAT acetylation, inhibition of the STAT1 :HDAC1
complex, and decreased occupancy of STAT1 on antiviral gene promoters. We
used siRNA to specifically identify HDACs 1 and 3 as being critical for IFNamediated anti-HCV activity. Finally, we showed that boosting HDAC gene
expression by theophylline supplementation improved IFNa-mediated antiviral
gene expression and anti-HCV activity, thus supporting the hypothesis that
HDACs are critical for IFNa anti-HCV signaling.

Impaired SAM metabolism, as a result of increased intracellular Sadenosylhomocysteine, markedly reduced IFNa-mediated antiviral gene
expression and anti-HCV activity, which correlated with a decrease in STAT
phosphorylation and an increase in association between STAT1 and its negative
regulator PIAS 1. We also showed that impaired SAM metabolism downregulated
expression of several HDACs, which may also impact IFNa antiviral signaling.
Importantly, SAM supplementation restored the antiviral and anti-HCV properties
of IFNa.

Acrolein, an environmental pollutant, significantly inhibited antiviral gene
expression, which correlated to impaired STAT phosphorylation, decreased
induction of class I HDAC mRNAs, and reduced HDAC activity in human
hepatoma cells. The results presented herein reveal a critical role for HDACs
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and SAM metabolism in IFNa-mediated anti-HCV activity and support the use of
SAM and/or inducers of HDACs as adjunct therapy in managing HCV infection.

Vll

TABLE OF CONTENTS
PAGE
ACKNOWLEDGEMENTS .....................................................................iv
ABSTRACT .......................................................................................v
LIST OF FIGURES ..............................................................................xii

CHAPTER
I. INTRODUCTION ..................................................................... 1
Hepatitis C Virus (HCV) ....................................................... 1
Interferon-alpha (IFNa) and HCV ........................................... 3
S-adenosylmethionine (SAM) and HCV ................................... 6
Acrolein and HCV ...............................................................9
Epigenetics ....................................................................... 10
Hypothesis ........................................................................ 13
II. MATERIALS AND METHODS .................................................... 14
Cell Culture and Treatment. .................................................. 14
Reagents and Antibodies ..................................................... 15
Western Blot. .................................................................... 16
Immunoprecipitation ............................................................ 16
RT-PCR ........................................................................... 17
Transfections ..................................................................... 19
Luciferase Reporter Assay ................................................... 20

viii

Chromatin Immunoprecipitation (ChiP) Assay .......................... 20
HDAC Activity Assay ...........................................................21
SAM and SAH Measurement by HPLC ................................... 21
Statistical Analysis ..............................................................22
III. RESULTS ..............................................................................23
Histone Deacetylases and IFNa Signaling ................................ 23
Class I HDACs are required for IFNa-mediated antiviral signaling in
human hepatoma cells ........................................................23
Class I HDACs are required for IFNa-mediated antiviral signaling in
primary human hepatocytes .................................................26
Class I HDACs are required for retention of pSTAT1 in the nucleus
of human hepatoma cells .................................................... 28
Inhibition of HDACs decreases STAT1 :HDAC1 and correlates with
increased STAT1 acetylation ................................................ 30
Class I HDACs are required for IFNa-mediated PKR and ISG15
protein expression and suppression of viral NS5A protein ........... 31
Class I HDACs are required for association of STAT1 with the IRF1 promoter ........................................................................33
HDACs 1 and 3 are required for IFNa-mediated antiviral signaling in
human hepatoma cells ........................................................34
Theophylline boosts HDAC1 gene induction and improves IFNamediated anti-HCV gene induction and activity ........................ 39
Summary of data ...............................................................41

IX

Impaired SAM Metabolism and IFNa Signaling ....................... .43
Impaired SAM metabolism decreases methylation potential in
human hepatoma cells ....................................................... .43
Impaired SAM metabolism blocks IFNa-induced antiviral gene
expression in human hepatoma cells ..................................... .44
Impaired SAM metabolism blocks IFNa-induced activation of the
ISRE in antiviral gene promoters .......................................... .47
Impaired SAM metabolism inhibits IFNa-mediated pSTAT1, OAS,
and PKR protein expression in human hepatoma cells .............. .48
Impaired SAM metabolism increases STAT1 :PIAS1, which
correlates with decreased STAT1 :PRMT1 in the nucleus of human
hepatoma cells .................................................................. 51
SAM supplementation boosts IFNa-mediated antiviral gene
induction and anti-HCV activity in human hepatoma cells ............ 52
Impaired SAM metabolism downregulates HDAC gene induction in
human hepatoma cells ........................................................55
Summary of data ............................................................... 59
Acrolein and IFNa Signaling ................................................. 60
Acrolein inhibits IFNa-mediated antiviral gene expression and antiHCV activity in human hepatoma cells .................................... 60
Acrolein suppresses class I HDAC activity and gene expression in
human hepatoma cells ........................................................62
Summary of data ...............................................................65

x

IV. DiSCUSSiON .........................................................................66
V. CONCLUSiONS ........... ...................................................... ..... 74
REFERENCES ....... ........................................................................... .. 76
CURRICULUM ViTAE ...........................................................................88

Xl

LIST OF FIGURES

FIGURE

PAGE

1. Schematic of IFNa-stimulated JAKISTAT signaling .................................. 5
2. SAM metabolism schematic ................................................................ 8
3. Effect of HATs and HDACs on chromatin structure ................................. 12
4. Class I HDACs are required for IFNa-mediated antiviral gene expression via
the ISRE in human hepatoma cells ...........................................................24
5. Class I HDACs are required for IFNa-mediated anti-HCV activity ................ 26
6. Class I HDACs are required for IFNa-mediated antiviral gene expression in
primary human hepatocytes .....................................................................27
7. Class I HDACs are required for retention of pSTAT1 in the nucleus of human
hepatoma cells .....................................................................................29
8. Class I HDACs are required for IFNa-mediated STAT1 :HDAC1 association
and to prevent acetylation of STAT1 in the nucleus of human hepatoma cells ... 31
9. Class I HDACs are required for IFNa-mediated expression of the antiviral
proteins PKR and ISG15 and suppression of viral NS5A protein in human
hepatoma cells ........................................................................................32
10. Class I HDACs are required for association of STAT1 with the IRF-1
promoter in human hepatoma cells ..........................................................34
11. Silencing of HDACs in human hepatoma cells ...................................... 35

XlI

12. HDAC1 and HDAC3 are required for IFNa-mediated antiviral gene
expression in human hepatoma cells ........................................................ 36
13. HDAC1 and HDAC3 are required for IFNa-mediated PKR protein expression
and IFNa-mediated STAT1 :HDAC1 association in human hepatoma cells ........ 38
14. Theophylline enhances IFNa-mediated PKR mRNA induction and anti-HCV
activity and boosts HDAC1 mRNA induction in human hepatoma cells ........... .40
15. Schematic representation of the role of HDACs in IFNa-mediated anti-HCV
gene expression in hepatocytes ............................................................. .42
16. Impaired SAM metabolism inhibits IFNa anti-HCV activity in human
hepatoma cells ....................................................................................45
17. Impaired SAM metabolism inhibits IFNa-mediated antiviral gene induction
and anti-HCV activity in human hepatoma cells .......................................... 46
18. Impaired SAM metabolism inhibits IFNa-mediated activation of the ISRE in
human hepatoma cells ......................................................................... .48
19. Impaired SAM metabolism inhibits IFNa-mediated pSTAT1, OAS, and PKR
protein expression in human hepatoma cells ............................................. 50
20. Impaired SAM metabolism decreases STAT1 :PRMT1 and increases
STAT1 :PIAS1 association in the nucleus of human hepatoma cells ............... 52
21. SAM boosts IFNa-mediated antiviral gene induction and anti-HCV activity in
human hepatoma cells ..........................................................................53
22. SAM restores IFNa-mediated anti-HCV activity that was blocked by inhibition
of SAM metabolism ..............................................................................54

Xlll

23. Effect of impaired SAM metabolism on class I HDAC gene induction in
human hepatoma cells ..........................................................................56
24. Effect of impaired SAM metabolism on class II HDAC gene induction in
human hepatoma cells ..........................................................................57
25. Acrolein inhibits IFNa-mediated antiviral gene expression and ant-HCV
activity in human hepatoma cells .............................................................61
26. Acrolein decreases HDAC activity in human hepatoma cells ..................... 62
27. Acrolein decreases HDAC gene induction in human hepatoma cells .......... 64

XIV

CHAPTER I
INTRODUCTION

Hepatitis C Virus

Hepatitis C virus (HCV) infection is a major cause of acute hepatitis and chronic
liver disease in the United States (US) and is known to be a precursor to
cirrhosis, end-stage liver disease, hepatocellular carcinoma (HCC) and death. It
is estimated that more than 170 million persons worldwide are chronically
infected with HCV and approximately 3 million of those live in the US 5 , 66, 68,104.
The most recent statistics from the Centers for Disease Control and Prevention
suggest that 55-85% of HCV infected subjects will develop chronic infections.
Additionally, HCV remains one of the leading causes of liver transplantation in
the US and is a huge burden on the US healthcare system; it is estimated that
annual total medical costs for HCV patients will exceed $80 billion over the next
15 years 51 , 122.

HCV is an enveloped, single-stranded RNA virus of the family Flaviviridae. The
HCV genome is comprised of a single open reading frame (ORF) that is flanked
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by 5' and 3' non-coding regions (NCR). The ORF encodes a polyprotein that is
cleaved, both co- and post-translationally, to give rise to HCV core and envelope
proteins as well as several nonstructural (NS) proteins. The NS5B protein
functions as an RNA dependent RNA polymerase while other NS proteins
function as proteases necessary for processing of the polyprotein 17,55,68.
Importantly, the NS5A protein contains the interferon sensitivity determining
region (ISDR), which is highly susceptible to mutations and is thought to
determine early response to IFNa therapl1, 96,101,103. The 5' NCR contains an
internal ribosomal entry site (IRES) and the 3' NCR contains elements that are
required for efficient viral replication. The HCV genome has a great propensity
for mutations, thereby producing many HCV variants, and this quality is thought
to be related to its ability to induce chronic infection 17,72,119. This high mutation
rate may also make it difficult to develop vaccines against HCV.

HCV infection leads to the release of endogenous cytokines that invoke immune
and inflammatory responses to aid in viral clearance. Of particular importance is
induction of interferon alpha (IFNa), which activates the JAKISTAT signaling
pathway, ultimately leading to expression of IFNa-stimulated antiviral genes.
However, the virus also induces several countermeasures that inhibit the antiviral
activity of IFNa including induction of protein phosphatase 2A (PP2A) and
suppressor of cytokine signaling 1 and 3 (SOCS-1, SOCS-3), which interfere with
JAKISTAT signaling 11,52,69,104.
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Unfortunately, more than 75% of individuals infected with HCV show no signs or
symptoms and the disease is usually not detected until it is in the chronic stage.
Additionally, HCV infection can worsen underlying disease if it coexists with other
hepatic conditions, such as alcoholic liver disease 122. There is no vaccine
against HCV and the current FDA approved standard of care is pegylated-IFNa
combined with ribavirin. Despite the antiviral properties of IFNa, up to 60% of
patients fail to reach sustained virological response (SVR) particularly those
infected with HCV genotype 1, which is most prevalent in the US. Response to
IFNa therapy is dependent on several factors including viral load, obesity, alcohol
consumption, smoking, and exposure to environmental pollutants35 , 117, 122. In
addition, the pegylated-IFNa/ribavirin treatment regimen is expensive and
produces many harsh side effects. In 2011, two new protease inhibitors,
boceprevir and telaprevir, were FDA-approved for treatment of HCV; however,
they must be used in combination with pegylated-IFNa and ribavirin therapy and
they are only effective against HCV genotype 1. Additionally, each of these
protease inhibitors has a complicated dosing regimen, produces harsh side
effects, and has numerous contraindications. Therefore, the need for enhancing
the efficacy of the existing IFNa treatment is of critical importance.

IFNa ANTIVIRAL SIGNALING and HeV

IFNa is a ubiquitous cytokine with immunomodulatory and antiviral properties.
IFNa is released from host cells and given as medication during HCV infection to
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aid in clearance of the virus. The antiviral action of IFNa is mediated through
binding with the cell surface receptors IFNAR1 and IFNAR2, which activates the
JAKISTAT signaling pathway, ultimately leading to expression of IFNa-stimulated
antiviral genes. Critical steps in this pathway include IFNa-mediated
phosphorylation of the receptor-associated kinases Jak1 and Tyk2, which
provides docking site for the inactive STAT proteins. Docking of STAT induces
its phosphorylation on tyrosine residue 701 and serine residue 727. Once
activated, the pSTAT proteins dissociate from the receptor and form STAT
dimers that are translocated to the nucleus. Tyrosine phosphorylation of
cytoplasmic STAT proteins is necessary for their dimerization and subsequent
nuclear import while serine phosphorylation is required for optimal transcriptional
activity. Once inside the nucleus, pSTATs associate with the transcription factor
IRF-9 to form the interferon stimulated gene factor 3 (ISGF 3) transcription
complex. ISGF3 binds the interferon stimulated response element (ISRE) within
the promoter of IFNa stimulated genes and induces expression of several
antiviral proteins including dsRNA-activated protein kinase (PKR) and
oligoadenylate synthetases (OAS), which arrest viral protein synthesis and
degrade viral RNAs, respectively38, 42, 63, 67, 93, 100, 107, 121, 127.
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Figure 1: Schematic of IFHa-stimulated JAKISTAT signaling. Modified from
http://www.springerimages.com/lmages/MedicineAndPub/icHealthl110.1007 s11154-008-9089-x-1

Negative regulation of JAKS/STAT signaling occurs via several mechanisms.
Nuclear pSTATs can be deactivated by phosphatases, which inhibits IFNamediated transcription. Additionally, STAT forms a complex with the histone
acetyltransferase (HAT) protein,

esp,

inside the nucleus, thus causing

acetylation of STAT, which subsequently leads to its nuclear export, and arrested
transcription of IFNa-stimulated antiviral genes

58,61 ,62.

IFNa-mediated antiviral

gene activation is also inhibited by association of STAT1 with protein inhibitor of
activated STAT (PIAS1) inside the nucleus of cells

73, 120.

Importantly, arginine

methylation of STAT1 prevents the STAT1 :PIAS1 association, and STAT1
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methylation is also required for optimal transcriptional activitl5 , 120. Additionally,
histone deacetylase (HDAC) activity, which recruits RNA polymerase to the
promoter of IFNa stimulated genes, is required for antiviral gene expression 99 .

HCV induces several countermeasures to inhibit the antiviral activity of IFNa
including induction of protein phosphatase 2A (PP2A), SOCS-1, and SOCS-3, all
of which interfere with JAKISTAT signaling 11,27,42,43,73. Specifically, SOCS-1
and SOCS-3 interact with receptor associated JAK to block its kinase activity,
thereby preventing STAT phosphorylation. PP2A interferes with the signaling
cascade by inhibiting protein arginine methyltransferase (PRMT)-mediated
methylation of STAT proteins, which allows for association between STAT1 and
its negative regulator, PIAS1 11 , 27,107. HCV also induces oxidative stress that
impacts HDAC activity84. These alterations in HDAC activity might also affect the
anti-HCV action of IFNa as HDACs are required to recruit RNA polymerase to the
promoters of IFNa-stimulated genes86 ,99.

S-adenosylmethionine and HCV

S-adenosylmethionine (SAM) is of pivotal importance in cellular metabolism,
serving as the major donor of methyl groups in transmethylation and
transsulfuration reactions 6 , 14, 18,76. The majority of SAM synthesis occurs in the
liver, whereby the adenosyl group from ATP is transferred to the sulfur atom in
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methionine, in a reaction catalyzed by methionine adenosyltransferase (MAT).
Once formed, SAM is rapidly metabolized to S-adenosylhomocysteine (SAH) by
specific methyltransferases (MT) that transfer the methyl group from SAM to
various molecules, including nucleic acids, proteins, and phospholipids. SAH
hydrolase (SAHH) hydrolyzes SAH to yield adenosine and homocysteine, which
is then converted back to methionine in a series of reactions catalyzed by
homocysteine methyltransferase 6, 14,47,80. The reaction catalyzed by SAHH is
the only reversible reaction in the SAM metabolism pathway and the equilibrium
favors the formation of SAH, however, the rapid uptake of adenosine and
homocysteine by the cell drives the reaction in the direction of catalysis.
Importantly, SAH is a potent inhibitor of cellular MTs, thus any increase in
intracellular SAH levels will have detrimental effects on several transmethylation
reactions. Methylation is essential for synthesis of several cellular components,
including DNA and proteins, thus, intracellular SAM levels are critical for normal
cell development and function. The ratio between SAM and SAH, called the
methylation potential (MP), must be controlled for normal cellular function.
Increases in intracellular SAH will decrease MP and block critical methylation
reactions leading to abnormal cellular function 6, 14,47,80. Several studies have
shown that MAT1A mRNA levels are markedly reduced in patients with chronic
liver disease, liver cirrhosis, or HCc5 , 75. Importantly, elevated serum levels of
SAH have been documented in patients with chronic liver disease 6 , 75, 77.
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Figure 2: SAM metabolism schematic.

In cell culture systems, SAM metabolism can be disrupted by several
mechanisms that raise intracellular SAH levels, thereby decreasing the
SAM/SAH ratio and methylation potential. Targeting SAHH with pharmacologic
inhibitors is an indirect mechanism to impair SAM metabolism. In 1977, Chiang
et al. first reported the use of 3'-deazaadeonsine (DZA), a nucleoside analog of
adenosine, as a potent inhibitor of SAHH that raised intracellular SAH and
decreased SAM/SAH. Over the years, several other nucleoside analogs have
been discovered that inhibit SAHH, including adenosine dialdehyde (AD)

7, 19, 20.

Both DZA and AD bind to and inhibit SAHH leading to an increase in intracellular
SAH and a decrease in methylation potential.
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Pharmacologic SAHH inhibitors

are a valuable tool for studying the effects of impaired SAM metabolism but
inhibition of SAHH is only one mechanism that increases intracellular SAH.
Since the products of SAH hydrolysis are adenosine and homocysteine and the
equilibrium of the reversible SAHH reaction lies in the direction of SAH synthesis,
administration of exogenous adenosine and homocysteine will also impair SAM
metabolism by increasing intracellular SAH levels

47

.

Acrolein and HeV

HCV disease progression and response to IFNa therapy depend on a variety of
factors including obesity, oxidative stress, and external factors such as smoking,
alcohol consumption, and exposure to environmental pollutants 35 , 117, 122.
Acrolein is a highly reactive

a,~-unsaturated

aldehyde that humans are exposed

to in a variety of situations. Importantly, acrolein is found in all sources of smoke
including cigarette smoke, car exhaust, overheated cooking oils, and smoke from
burning wood. Acrolein is also formed endogenously as a product of lipid
peroxidation, a process that is also stimulated by acrolein, and is associated with
oxidative stress 54 , 56, 65, 90. Recent studies also suggest that acrolein alters HDAC
activit;. HDAC activity is required to recruit RNA polymerase to the promoters
of IFNa-stimulated antiviral genes and is critical for efficient transcription of these
genes. Accordingly, it is reasonable to speculate that exposure to acrolein may
contribute to poor response to anti-HCV therapy.
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Epigenetics
A growing body of evidence suggests that DNA methylation and posttranslational histone modifications are important changes that will impact disease
progression by inducing alterations in gene transcription, chromatin configuration,
and DNA integriti' 41, 60, 86,111. Generally, CpG island methylation, which is
mediated by DNA methyltransferases (DNMTs), results in transcriptional
repression due to recruitment of methyl-CpG binding proteins, HDACs, and
chromatin remodeling complexes 1. The modifications of lysine (K) residues on
histone tails are indeed more complex. Histones associate with DNA to form
nucleosomes, the fundamental repeating unit of eukaryotic chromatin.
Specifically, 2 copies of each of the core histone proteins (H2A, H2B, H3, and
H4) come together to form a histone octomer, which wraps 147 basepairs of
DNA, thus forming a nucleosome. Nucleosomes function to package DNA into
chromatin: euchromatin is loosely packaged and associated with active
transcription, whereas heterochromatin is tightly packaged and associated with
repressed transcription. Importantly, the modifications of the highly conserved
histone tails are what facilitate DNA packaging 1,60, 111. The well-characterized
modifications of histones occur on lysine (K) residues on the histone tails. In
addition to methylation, it has been established that K residues are subject to
modification by phosphorylation, acetylation, and ubiquitination. The most
characterized modifications are methylation and acetylation, which are generally
thought to repress and activate transcription, respectivell4, 111, 124. Importantly,
these modifications are driven by various MTs, HDACs, and histone acetyl

10

transferases (HATs). It should be noted, however, that each K residue may be
subject to more than one type of modification and these modifications may have
different effects depending on the nature of local chromatin structure 60 , 64,111,124.

DNA methylation and histone modifications work together to regulate gene
transcription. In most cases, transcriptionally repressed genes are
hypermethylated at CpG islands and associated with hypoacetylated histone H3
that is methylated on the K9 residue (H3K9Me). Transcriptionally active genes
are hypo methylated at CpG islands and associated with hyperacetylated and K4
methylated H3 (H3K4Me)111, 124. Importantly, SAM functions as the major methyl
donor during epigenetic modifications, so maintaining SAM and SAM/SAH levels
are critical for methylation of DNA and histones.

HDACs and HATs were historically named based on their ability to modify K
residues on histone tails. HATs add negatively charged acetyl groups to K
residues, which repel the negatively charged DNA, and are associated with
loosely packed euchromatin and active transcription. HDACs remove the acetyl
groups, which leads to attract of the histones to the DNA, and correlate with
tightly packed heterochromatin and repressed transcription.
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Figure 3: Effect of HATs and HDACs on chromatin structure. Modified from
http://missinglink.ucsf.edu/lm/genes_and_genomes/acetylation.html

More recently, there has been an increasing body of evidence showing that
HDACs and HATs, as well as MTs, also work on non-histone proteins

41, 87, 124.

Importantly, HDACs have been implicated in the regulation of signaling by
various transcription factors 41 . IFNa-mediated antiviral gene expression relies on
phosphorylation and nuclear import of STAT. Nuclear STAT proteins can be
acetylated by CBP, a HAT protein , which marks STAT for nuclear export and
leads to reduced antiviral gene transcription 58 , 62. In addition to being required to
recruit RNA polymerase to IFNa-stimulated gene promoters, HDACs may playa
role in IFNa anti-HCV gene expression by preventing STAT acetylation and
increasing nuclear retention of activated STAT proteins.
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Overall Hypothesis:

The molecular mechanisms, which include both viral and host factors, involved in
resistance to IFNa anti-HCV therapy are only beginning to be understood. A
better understanding of these regulatory mechanisms may prove to be beneficial
for enhancing the efficacy of IFNa. Recent data strongly suggest that HDACs
and methylation playa critical role in regulation of IFNa signaling and antiviral
gene expression. Importantly, HCV is known to modify HDAC activity and
impaired SAM metabolism is a well-documented feature of chronic liver injury6, 77,
84.

Based on these findings, we hypothesized that HDACs and SAM play

critical roles in regulating IFNa signaling and epigenetic regulation of antiHCV gene expression in hepatocytes.
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CHAPTER II
MATERIALS AND METHODS

Cell Culture and Treatment:
Huh7 cells (Apath, LLC, St. Louis, MO) were gown in Dulbecco's modified eagle
medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 U/ml
penicillin, 10 IJg/ml streptomycin, and 1x non-essential amino acids (NEAA).
Huh7 cells stably transfected with an HCV replicon (HCVR) (clone B (S11791),
Apath, LLC, St. Louis, MO) were grown in DMEM media supplemented with 10%
FBS, 10 U/ml penicillin, 10 IJg/ml streptomycin, 1x NEAA, and 1mg/ml G418.
Primary human hepatocytes were purchased from Zen-Bio (Research Triangle
Park, NC) and maintained as per manufacturer's protocol. All cells were
maintained in a 37°C and 5% C02 incubator. Cells were treated at a density of
1.0 x 106 cells/ml in all experiments unless otherwise noted. For HDAC studies,
cells were treated with the HDAC inhibitors tricostatin A (TSA, 400 ng/ml) or
suberic bishydroxamate (SBHA, 10 IJg/ml) 30 minutes before stimulation with
IFNa. Alternatively, cells were treated with the HDAC inducer, theophylline (1
mM), for 24 hours prior to IFNa treatment. For SAM metabolism studies, cells
were treated with the SAM metabolism disruptors, adenosine + homocysteine

14

(AdenHcy, 1mM), adenosine dialdehyde (AD, 80
(DZA, 80

~M)

~M),

or 3-deazaadeonsine

3 hours prior to IFNa. For SAM supplementation studies, cells

were treated for 24 hours with 1 mM SAM prior to IFNa treatment. To study the
effects of SAM supplementation on impaired SAM metabolism, cells were treated
with SAM metabolism inhibitors for 3 hours, then SAM for 24 hours, prior to
stimulation with IFNa. For acrolein (ACR) studies, cells were treated with 25 or
50

~M

ACR in serum-free DMEM for 30 minutes prior to IFNa treatment.

Reagents and Antibodies:
AD, DZA, adenosine, homocysteine, SAM, TSA, SBHA, ACR, theophylline and
protease inhibitor cocktail were purchased from Sigma-Aldrich (St. louis, MO).
Total STAT1and phospho-STAT1 (Tyr 701 and Ser 727) primary and goat antirabbit horseradish peroxidase conjugated secondary antibodies were purchased
from Cell Signaling (Danvers, MA). Anti-dimethyl arginine primary antibody was
purchased from Abcam, Inc (Cambridge, MA). HCV NS5A antibody was a kind
gift from Dr. Charles M. Rice (Rockefeller University). Protein AlG plus agarose
was purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA). Fetal
bovine serum was purchased from Atlanta Biologicals (Norcross, GA). Trisbuffered saline (TBS), DMEM, G418, NEAA, Trizol, and pre-stained protein
ladder were purchased from Invitrogen (Carlsbad, CA). ECl western blotting
detection reagent was purchased from Amersham Biosciences (Piscataway, NJ).
Human IFNa was purchased from PBl Biomedical laboratories (Piscataway,
NJ). Reagent for cDNA synthesis was purchased from Quanta BioSciences
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(Gaithersburg, MD). SYBR Green RT-PCR reagent was purchased from Applied
Biosystems (Foster City, CA). HCV PCR primer was purchased from Alpha DNA
(Montreal, Canada). All other PCR primers were purchased from Integrated DNA
Technologies (Coralville, IA).

Western Blot:
Cytoplasmic and nuclear protein extracts were prepared according to Dignam 23 .
For whole cell Iysates, cells were washed twice with cold PBS and lysed with
NETN buffer (150 mM NaCI, 1mM EDTA, 20 mM Tris-HCI pH 8.0, 10% glycerol,
0.5% Nonidet P-40, 1x protease inhibitor cocktail, sodium vanadate). Extraction
buffers were supplemented with 1IJM TSAlml for acetylation studies. Proteins
were separated by SDS-PAGE and transferred to PVDF membranes.
Membranes were incubated in the appropriate primary antibodies overnight with
gentle agitation at 4°C, washed with TBS-Tween, and incubated with the
appropriate secondary antibodies for 1 hour. Proteins were visualized using ECl
detection reagent as per the manufacturer's protocol. Pre-stained protein ladder
was used to estimate the size of the transferred proteins.

Immunoprecipitation:
6

5 x 10 hepatoma cells were untreated or treated with SAM metabolism inhibitors
for 3 hrs, HDAC inhibitors for 24 hours, and/or IFNa for 30 minutes. Following
treatment, cells were washed 2 times with cold PBS and proteins were extracted
as for western blot. Protein concentration was determined using Bio-Rad protein
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assay per the manufacturer's protocol. Equivalent amounts of protein (250-500
I-/g protein/sample) were adjusted to a volume of 500 1-/1 in PBS and incubated
with immunoprecipitation antibody overnight with gentle agitation at 4°C. The
following day, 20 1-/1 of protein AlG plus agarose beads was added for 3 hours
with gentle agitation at 4°C. The immunoprecipitates were washed 4 times with
PBS and the beads were subsequently resuspended in 40 1-/1 of 3x SOS-PAGE
sample buffer, heated for 3 minutes at 95°C, briefly centrifuged, and 30 1-/1 of
sample was separated by SOS-PAGE and subjected to the Western blotting
procedure.

RT-PCR:
Real-time polymerase chain reaction (RT-PCR) assays were used to assess 2'5'
OAS and PKR mRNA levels in Huh? cells and HCV RNA levels in HCVR cells.
Total RNA was isolated from treated cells, after 2 hours (Huh?) or 24 hours
(HCVR) of stimulation with IFNa, using TRlzol according to manufacturer's
instructions. For real time PCR, the first strand cONA was synthesized using 200
ng of total RNA and qScript cONA SuperMix (Quanta BioSciences) according to
manufacturer's protocol. The RT conditions were 5 minutes at 25°C, 30 minutes
at 42°C and 5 minutes at 85°C. Reactions in which the RNA was omitted served
as negative controls. Real time PCR was performed with an ABI prism ?500
sequence detection system using SYBR green I dye reagents. The specific
primers were designed for human GAPOH, 2'5' OAS, PKR, ISG15, and HOACs
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1-10, as well as HCV, using Primer3 software program. The following primers
were used in real-time PCR:
hGAPDH-RT-FP: 5' CTCTGCTCCTCCTGTTCGAC 3'
hGAPDH-RT-RP: 5' TTAAAAGCAGCCCTGGTGAC 3'
h 2'5'-OAS-RT-FP: 5' GCAGAAAGAGGGCGAGTTCT 3'
h 2'5'-OAS-RT-RP: 5' CCTGGGCTGTGTTGAAATGT 3'
hPKR-RT-FP: 5' CTTTGGCACCCAGATTTGAC 3'
hPKR-RT-RP: 5' AAACTTGGCCAAATCCACCT 3'
hISG15-RT-FP: 5' CCCACAGCCATGGGCT 3'
hISG15-RT-RP: 5' CGATCTTCTGGGTGATCTGC 3'
hHDAC1-RT-FP: 5' CATCTCCTCAGCATTGGCTT 3'
hHDAC1-RT-RP: 5' GACGGGGATGTTGGAAATTA 3'
hHDAC2-RT-FP: 5' CAGCAAGTTATGGGTCATGC 3'
hHDAC2-RT-RP:5' CCATGGCGTACAGTCAGGGA 3'
hHDAC3-RT-FP: 5' GTTGTTCAGCTGGGTTGCTC 3'
hHDAC3-RT-RP: 5' GAGAGTCAGCCCCACCAATA 3'
hHDAC4-RT-FP: 5' AGGATTCAGCAGCTCCACTG 3'
hHDAC4-RT-RP: 5' GAGCTCGTTGGAGCTATCGT 3'
hHDAC5-RT-FP: 5' AGTGTGGGGTCCACAGAGC 3'
hHDAC5-RT-RP: 5' ACTTCTCTGCACAGCATCCC 3'
hHDAC6-RT-FP: 5' TCCAAGGCACATTGATGGTA 3'
hHDAC6-RT-RP: 5' CACAGTTCACCTTCGACCAG 3'
hHDAC7-RT-FP: 5' CACTGGTGCTTCAGCATGAC 3'
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hHDAC7-RT-RP: 5' GGCTCAGTCTTCCCCAGC 3'
hHDAC8-RT-FP: 5' CCAGCACATAATCAGGACCA 3'
hHDAC8-RT-RP: 5' ATTTTGGGAGGAGGAGGCTA 3'
hHDAC9-RT-FP: 5' CCTCTCACGGACAACAGGGT 3'
hHDAC9-RT-RP: 5' TGCACAGTATGATCAGCTCAG 3'
hHDAC10-RT-FP: 5' GGCTGGAGTGGCTGCTATAC 3'
hHDAC10-RT-RP: 5' CTGAGGGAGGAGACAGAAGC 3'
HCV-RT-FP: 5' ATGGCGTTAGTATGAGTGTC 3'
HCV-RT-RP: 5' GGCATTGAGCGGGTTGATC 3'

The relative gene expression was analyzed using

ZMCI

method by normalizing

with GAPDH gene expression in all experiments.

Transfections:
For siRNA transfections, Huh7 cells were plated in a 6-well plate at 0.3x1 06
cells/well the day before transfection. On the day of transfection, cells were
placed in serum- and additive-free DMEM prior to transfection. The siRNA
transfection complex was prepared in sterile PBS using Fugene HD transfection
reagent at the 3:2 (IJI Fugene: IJg DNA) ratio according to manufacturer's
protocol and was allowed to incubate at room temperature for 15 minutes before
dropwise addition to the appropriate wells, with swirling. After 6 hours, media
was replaced with complete DMEM and transfection was continued for 48 hours
(RNA) or 72 hours (protein) prior to stimulation with IFNa. After 48 hours, cells
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that were transfected for protein extraction were trypsinized, transferred to new
6-well plates, and allowed to incubate an additional 24 hours. For ISREluciferase transfections, Huh? cells were plated at ?x1 06 cells in a T?5 flask the
day before transfection. On the day of transfection, transfection complex was
made by adding 18 1-11 of Fugene HD and 6 I-Ig ISRE-Iuciferase cis-reporting
plasmid (Sratagene, La Jolla, CA) to 562 1-11 of serum-free DMEM containing
pen/strep. Transfection complex was allowed to incubate at RT for 15 minutes
before dropwise addition to the flask with swirling. The flask was incubated for
24 hours and cells were then replated in a 24-well plate at 0.5x1 0 6 cells/well.
Cells were allowed to adhere for 2 hours before treatment.

Luciferase Reporter Assay:
For cell lysis and detection of luciferase activity, a commercialluciferase assay
kit (Promega, Madison, WI) was used according manufacturer's protocol.
Luciferase activity was quantified in an Orion luminometer and normalized to
protein concentration.

Chromatin Immunoprecipitation (ChiP) Assay:
Appropriately treated Huh? or HCVR cells were fixed with 1% formaldehyde for
10 minutes at RT. To stop fixation, 1.25M glycine was added to a final
concentration of 0.125M in media and allowed to incubate for 5 minutes at RT.
Media was removed from cells and cells were washed twice with PBS containing
1x protease inhibitor cocktail (Sigma Aldrich) and 5mM sodium butyrate.
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Following the wash, PBS was drained from the cells and chromatin was digested
using the SimpleChlP Enzymatic Chromatin IP Kit (Cell Signaling, Danvers, MA)
according to manufacturer's protocol. Chromatin concentration was measured
as DNA using Nanodrop and digestion of chromatin was analyzed using 6%
acrylamide gel. For immunoprecipitation, 20jJg of chromatin was diluted in ChiP
dilution buffer and incubated with 10jJg STAT1 antibody and 20jJi protein A
magnetic beads overnight at 4°C with rotation. The next day, the
immunocomplexes were washed and crosslinking was reversed following
manufacturer's protocol. After reversal of crosslin king, DNA was purified using
the UltraClean DNA Purification Kit (MO BIO Laboratories, Carlsbad, CA) and
subject to real-time PCR with specific primers for IRF-1 (SABiosciences,
Frederick, MD). To determine changes in STAT1 occupancy at the IRF-1
promoter, data were normalized to input and compared to UT cells.

HDAC Activity Assay:
The Epigenase HDAC Activity/Inhibition Direct Assay Kit (Epigentek,
Farmingdale, NY) was used according to manufacturer's protocol to measure
HDAC activity in nuclear Iysates.

SAM and SAH Measurement by HPLC:
Intracellular SAM and SAH levels were measured in deproteinized extracts as
described previously (Song, Zhou et al. 2007).
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Statistical Analysis:
All data are presented as mean ± standard deviation of the mean (SDM). The
method of analysis used was one-way analysis of variance (ANOVA) with the
Tukey-Kramer multiple-comparison test. Differences were considered
statistically significant for P

~

0.05.
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CHAPTER III
RESULTS

HISTONE DEACETYLASES AND INTERFERON-ALPHA SIGNALING

Class I HDACs are required for IFHa-mediated antiviral signaling in human
hepatoma cells.
The anti-HCV action of IFNa is due, in part, to its activation of antiviral genes
such as PKR, OAS, and ISG15. To examine the possible role of HDACs in
regulation of IFNa-mediated anti-HCV gene expression, a human hepatoma cell
line stably transfected with an HCV replicon (HCVR cells) was pretreated for 30
minutes with two class I HDAC inhibitors (HDACi), TSA and SBHA, followed by
stimulation with IFNa for 2 hours. Our data revealed that inhibition of class I
HDACs significantly downregulated induction of the IFNa-stimulated antiviral
genes. To confirm that this result was not an artifact of using a transfected cell
line, we conducted the same experiment in the parental Huh? cell line. As seen
with HCVR, pretreatment of Huh? cells with HDACi significantly inhibited IFNamediated induction of PKR, OAS, and ISG-15 (Fig. 4).
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Figure 4: Class I HDACs are required for IFNa-mediated antiviral gene
expression via the ISRE in human hepatoma cells. Human hepatoma cells
treated for 2 hours with 1OOUlmllFNa showed robust induction of the antiviral
genes PKR, OAS, and ISG15, which was significantly reduced by pretreatment
with TSA or SBHA. Pretreatment with TSA or SBHA also blocked IFNastimulated ISRE activation. Error bars indicate SDM (N=3; a=
P~

P~

0.05 vs UT, b=

0.05 vs IFN).

IFNa-mediated transcription of anti-HCV genes requires binding of the ISGF3
transcription complex to the ISRE, a cis-acting DNA sequence that is common in
antiviral gene promoters 38 , 42 , 63, 100. To determine if HDACi-induced suppression
of IFNa anti-HCV gene expression was due to impaired activation of the ISRE,
we analyzed ISRE-driven luciferase activation in Huh? cells. Briefly, cells were
transiently transfected with an ISRE-Iuciferase reporter plasmid and reseeded
into 24-well plates prior to treatment with HDACi for 30 minutes and stimulation
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with IFNa for 6 hours. Following stimulation, cells were lysed and equivalent
amounts of Iysates were measured for luciferase activity. Treatment with IFNa
alone caused robust activation of the ISRE, which was markedly inhibited by
pretreatment with HDACi (Fig. 4). These data suggest that the suppression of
IFNa stimulated antiviral genes caused by HDACi is partially due to impaired
transcriptional activation of ISRE in the promoters of the genes.

After evaluating the effects of HDACi on the host antiviral response, we were
interested in the effect of HDAC inhibition on IFNa-mediated suppression of HCV
RNA replication.

Preliminary experiments revealed that 10U/mllFNa was

sufficient to suppress HCV RNA induction by 50% after 24 hours of exposure.
To determine how HDACs affect the anti-HCV action of IFNa, HCVR cells were
pretreated for 30 minutes with HDACi prior to stimulation with 1OU/mllFNa for 24
hours. Interestingly, cells that were pretreated with HDACi showed significant
inhibition of IFNa-mediated suppression of HCV (Fig. 5). Taken together, these
results show that HDACi significantly inhibited expression of IFNa-stimulated
anti-HCV genes, which correlated to impaired activation of the ISRE and an
increase in HCV RNA induction. These data suggest a critical role for class I
HDACs in the regulation of IFNa-mediated anti-HCV activity. Importantly, these
data are comparable to data from other published reports that show a need for
HDACs in activation of inducible gene systems 41 , 124.
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Class I HDACs are required for IFNa-mediated antiviral signaling in primary
human hepatocytes.
Huh? cells are a well established model system for studying human hepatocytes
but consideration must be given to the fact they are cultured hepatoma cells and
may not exhibit the same response as primary human hepatocytes. To address
this issue, we analyzed the effects of HDACi on IFNa-mediated antiviral gene
expression in commercially available primary human hepatocytes. The primary
hepatocytes were stimulated for 3 hours with 1OOOU/mllFNa alone or after
exposure to HDACi for 30 minutes. Total RNA was extracted and RT-PCR was
used to analyze mRNA induction of the antiviral genes PKR, OAS, and ISG15.
IFNa alone led to a 3- to 15-fold induction of all antiviral genes, which was
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significantly inhibited by pretreatment with HDACi (Fig. 6). These results agree
with our data from the hepatoma cell lines and confirm the requirement of class I
HDACs in IFNa-mediated antiviral gene expression in human hepatocytes.
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Figure 6: Class I HDACs are required for IFNa-mediated antiviral gene
expression in primary human hepatocytes. Primary human hepatocytes
treated for 3 hours with 1OOOUlmllFNa showed robust induction of the antiviral
genes PKR, OAS, and ISG15, which was significantly reduced by pretreatment
with TSA or SBHA. Error bars indicate SDM (N=3; a=
vs IFN).
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P~

0.05 vs UT, b=

p~

0.05

Class I HDACs are required for retention of pSTAT1 in the nucleus of
human hepatoma cells.
The antiviral action of IFNa is mediated through activation of the JAKISTAT
pathway. Critical steps in this pathway include the phosphorylation and nuclear
import of STAT1. IFNa treatment leads to phosphorylation of STAT1 on Y701
and S727, which is required for nuclear translocation and transcriptional activity,
respectively38,100, 121,127. To determine if HDACs playa role in JAKISTAT
signaling, human hepatoma cells were pretreated with HDACi for 30 minutes
prior to stimulation with IFNa for various time pOints. Nuclear and cytoplasmic
proteins were analyzed by Western blot for pSTAT1 protein expression.

HDACi

did not inhibit phosphorylation of STAT 1, however, compared to cells stimulated
with IFNa alone, there was an obvious difference in partitioning of pSTAT1.
Expression of pSTAT1 (Y701 and S727) in cells exposed to only IFNa was
mostly localized to the nucleus whereas pretreatment with HDACi led to
cytoplasmic accumulation of pSTAT1. The partitioning of pSTAT1 was evident
as early as 15 minutes after exposure to IFNa and could still be seen after 60
minutes. Here, we show the partitioning 45 minutes after exposure to IFNa (Fig.
7). Blots were also probed with total STAT1 and showed equal loading between
samples except total STAT levels were markedly less in cytoplasmic Iysates that
received IFNa. To ensure our result was not due to uneven loading of our
protein samples, blots were probed with

~-actin

or histone H3 to confirm equal

loading in the cytoplasmic and nuclear extracts, respectively (Fig. 7, bottom
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panel). These data reveal of role for HDACs in the nuclear retention of activated
STATs during IFNa signaling.
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Figure 7: Class I HDACs are required for retention of pSTAT1 in the
nucleus of human hepatoma cells. Cytoplasmic (CE) and nuclear (NE)
protein extracts were collected from Huh 7 cells stimulated with IFNa alone, or
after pretreatment with TSA or SBHA, and analyzed by Western blot.
Pretreatment with HDACi decreased retention of pSTAT1 in the nucleus, which
correlated with accumulation of pSTAT1 in the cytoplasm, compared to cells
stimulated with IFNa alone. {3-actin and histone H3 antibodies were used to
confirm equal loading of proteins between cytoplasmic and nuclear samples,
respectively.
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Inhibition of HDACs decreases the association between HDAC1 and STAT1
in the nucleus of human hepatoma cells and correlates with increased
STAT1 acetylation.
It has been established that STAT1 can be acetylated in the nucleus, due to
binding with HATs such as CSP, which will lead to its translocation back out to
the cytoplasm 58 ,61,62. Since the acetylation status is due, in part, to a balance
between the activities of HATs and HDACs, we determined: 1) STAT1
interaction with HDACs in the nucleus; and 2) STAT1 acetylation status in
response to inhibition of HDACs. Using nuclear extracts from Huh? cells treated
with IFNa alone or after HDACi pretreatment, we performed
immunoprecipitations with an antibody against STAT1 and probed the nuclear
STAT1 proteins by Western blot for association with HDACs. In cells stimulated
with IFNa alone, there was a marked increase in association between STAT1
and HDAC1, which was blocked by pretreatment with HDACi (Fig. 8, top). Next,
we determined whether or not HDACi-induced dissociation of the IFNastimulated STAT1 :HDAC1 complex correlated to an increase in acetylation of
STAT1. Nuclear Iysates were immunoprecipitated with an acetylated-Iysine
antibody and probed for STAT1 by Western blot. The impaired association
between STAT1 and HDAC1, caused by HDACi pretreatment, correlated with an
increase in STAT1 acetylation not seen in cells that only received IFNa (Fig. 8,
bottom). These results suggest HDACs playa role in regulation of IFNamediated antiviral gene expression by binding STAT proteins to keep them
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deacetylated, thereby enhancing their retention in the nucleus and allowing for
active transcription.
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Figure 8: Class I HDACs are required for IFNa-mediated STAT1 :HDAC1
association and to prevent acetylation of STAT1 in the nucleus of human
hepatoma cells. (Top) Pretreatment with SBHA inhibited IFNa-stimulated
formation of STAT1:HDAC1 complex in the nucleus of Huh? cells. (Bottom)
Pretreatment with SBHA enhanced acetylation of STAT1 and correlated with
inhibition of the IFNa-stimulated STA T1 :HDAC1 complex.

Class I HDACs are required for IFNa-mediated antiviral PKR and ISG15
protein expression and suppression of viral NS5A protein expression.
RT-PCR data showed that HDACi caused significant inhibition of IFNa-mediated
host antiviral mRNA induction and suppression of HCV RNA, hence we wanted
to verify that these results correlated to suppression of host antiviral proteins and
viral proteins. We performed Western blots using whole cell Iysates from HCVR
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cells that were stimulated for 24 hours with IFNa alone and after 30 minute
pretreatment with HDACi. Using antibodies for the antiviral PKR and ISG15
proteins and the viral NS5A protein, we found that HDACi blocked both IFNastimulated antiviral protein expression and IFNa-mediated suppression of NS5A
(Fig. 9). These results are consistent with our PCR data and further support the
hypothesis that HDACs playa critical role in the anti-HCV actions of IFNa.

SBHA

T

IFN

+
IFN

PKR

ISG15

NS5A

_ - . . - -__-*1 J3.actin

Figure 9: Class I HDACs are required for IFNa-mediated expression of the
antiviral proteins PKR and ISG15 and suppression of viral NS5A protein in
human hepatoma cells. Western blot analysis of whole cell Iysates from IFNastimulated HCVR cells revealed an increase in antiviral PKR and ISG15 protein
expression, which correlated with a decrease in viral NS5A protein expression.
Pretreatment with SBHA inhibited IFNa-mediated antiviral protein expression and
suppression of NS5A. f3-actin antibody was used to confirm equal loading of
protein between samples.
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Class I HDACs are required for association of STAT1 with the IRF-1
promoter.
The results presented thus far clearly show that class I HDACs play an important
role in IFNa-stimulated activation of the JAKISTAT signaling cascade, host
antiviral gene induction and protein expression, and IFNa-mediated suppression
of HCV RNA and NS5A protein. Since HDACs also modify chromatin, we
wanted to determine if inhibition of HDACs modified the epigenetic landscape at
the promoter of the IFNa stimulated gene IRF-1 (interferon response factor 1).
We performed chromatin immunoprecipitation (ChiP) analysis using an antibody
for STAT1 and primers specific for the IRF-1 promoter. Briefly, appropriately
treated HCVR cells were fixed with formaldehyde to crosslink proteins to DNA,
nuclei were isolated and subjected to enzymatic digestion to cleave chromatin,
and the digested chromatin was incubated with primary STAT1 antibody and
magnetic beads. Following incubation, the immunocomplexes were washed,
crosslin king was reversed, and DNA was purified prior to analysis by RT-PCR.
As seen in Figure 10, HDACi pretreatment significantly decreased the
association of STAT1 with the IRF-1 promoter. This result correlated with the
significant downregulation of IFNa-stimulated antiviral genes seen previously as
STAT1 is part of the ISGF3 transcription complex that must be bound to the
promoter for active transcription of those genes. Taken together, our results
show that class I HDACs are essential for IFNa-mediated activation of the
JAKISTAT signaling cascade, association of transcription factors with the
promoters of ISGs, and IFNa-mediated suppression of HCV.
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Figure 10: Class I HDACs are required for association of STAT1 with the
IRF-1 promoter in human hepatoma cel/s. Chromatin was isolated from
HCVR cells stimulated with IFNa alone, or after pretreatment with TSA or SBHA,
and STAT1 occupancy at the IRF-1 promoter was analyzed by ChiP assay.
HDACi pretreatment decreased the IFNa-stimulated association of STAT1 with
the IRF-1 promoter. Result is representative of 2 independent experiments.

HDACs 1 and 3 are required for IFNa-mediated antiviral gene expression in
human hepatocytes.
Since the pharmacologic HDAC inhibitors SBHA and TSA block the activity of all
class I HDACs, we used siRNA to determine if any or all of the class I HDACs
were necessary for IFNa-mediated anti-HCV gene expression. Huh7 were plated
at a density of 0.3 x 106 cells/well and transfected for 72 hours with siRNA
specific for HDACs 1, 2, 3, or 8. Cells were transfected with a nonspecific
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scramble siRNA to serve as a negative control.

Following transfection , total

RNA and protein extracts were collected and used to verify knockdown of the
respective HDAC mRNAs and proteins (Fig. 11).
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Figure 11: Silencing ofHDACs in human hepatoma cells. Human hepatoma
cells were transfected with siRNA specific for HDACs 1 and 3 for 72 hours (RNA)
or 96 hours (protein), following the manufacturer's protocol. As negative
controls, cells were either treated with transfection reagent alone (NT) or nonspecific scramble siRNA (scr). (Left) Real-time PCR showed specific knockdown
of HDAC1 and HDAC3 mRNA induction by siHDAC1 and siHDAC3, respectively.

Error bars indicate SDM (N=3; a=

P~

0.05 vs NT) .

(Right) Western blot analysis of whole cell protein Iysates revealed that
siHDAC1 and siHDAC3 specifically suppressed expression of HDAC1 and
HDAC3 proteins, respectively. f3-actin antibody was used to verify equal loading
between protein samples.
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Once the specific knockdown of each HDAC was confirmed, the transfections
were repeated and cells were stimulated with IFNa to determine the specific
class I HDAC(s) that are critical for IFNa-mediated antiviral gene induction and
protein expression. We found HDACs 1 and 3 to be critical for IFNa-mediated
antiviral genes as silencing of those HDACs led to a partial, yet significant,
decrease in IFNa-mediated induction of PKR, OAS, and ISG15 (Fig. 12).
Silencing of HDACs 2 and 8 had no effect on induction of those antiviral genes.
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Figure 12: HDAC1 and HDAC3 are required for IFHa-mediated antiviral
gene expression in human hepatoma cells. Human hepatoma cells were

transfected with siRNA specific for HOAC1 or HOAC3 for 72 hours prior to
stimulation with 1OOUlmllFNa for 2 hours. Nontransfected (NT) cells were
treated with transfection reagent alone and served as the negative control. Realtime peR analysis showed transfection with siHOAC1 or siHOAC3 caused
partial, but significant, inhibition of IFNa-stimulated induction of PKR, OAS, and
ISG15. Error bars indicate SOM (N=3; a=
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P~

0.05 vs IFN).

After identifying HDACs 1 and 3 as being critical for IFNa-mediated antiviral gene
induction, we wanted to determine if silencing of these HDACs affected the
STAT1 :HDAC 1 association and/or expression of the antiviral protein, PKR. Using
whole cell Iysates from siRNA transfected cells, we performed an
immunoprecipitation using STAT1 antibody and looked for HDAC1 by western
blot. As expected, cells that did not express HDAC1 did not show a
STAT1 :HDAC1 association. Interestingly, silencing of HDAC3 also inhibited the
STAT1 :HDAC1 association (Fig. 13). Finally, silencing of both HDAC 1 and 3
decreased expression of the antiviral protein PKR (Fig. 13). These results
support the previous data using pharmacologic class I HDAC inhibitors and
specifically identify HDACs 1 and 3 as being critical for induction of IFNamediated anti-HCV gene expression.

37

siHOAC1 slHDAC3

NT

IFN

+
IFN

+
IFN
PKR

~-actin

IFNn
1

siHDAC3

IP: STAT1

WB: HDAC1

Figure 13: HDAC1 and HDAC3 are required for IFHa-mediated PKR protein
expression and IFHa-mediated STAT1:HDAC1 association in human
hepatoma cells. Huh7 cells were transfected with siRNA specific for HDAC1 or
HDAC3 for 96 hours prior to stimulation with 1000UlmllFNa for 1 hour. Nontransfected (NT) cells received transfection reagent alone and served as
negative control. (Top) Western blot analysis showed that siHDAC1 and
siHDAC3 suppressed IFNa-stimulated PKR protein expression. f3-actin antibody
was used to ensure equal loading of protein between samples. (Bottom)
siHDAC1 and siHDAC3 inhibited IFNa-induced STAT1:HDAC1 complex
formation in whole cell protein Iysates.
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Theophylline boosts HDAC1 gene induction and improves IFNa-mediated
anti-HCV gene induction and activity.
After confirming the requirement for HDACs in the regulation of IFNa-mediated
anti-HCV activity, we wanted to determine if boosting HDACs could improve the
antiviral actions of IFNa. Recent reports implicate theophylline in boosting HDAC
activity and modifying inducible signaling pathways 22, 53, 128. To elucidate the role
of theophylline in IFNa-mediated anti-HCV activity, HCVR cells were treated for
48 hours with increasing doses of theophylline prior to stimulation with IFNa for
24 hours. Total RNA was extracted and used to analyze PKR mRNA induction
and HCV RNA by RT-PCR. As seen in Figure 14, theophylline boosted IFNamediated PKR mRNA induction and enhanced its anti-HCV action. Importantly,
theophylline alone induced PKR and HDAC1 mRNA and suppressed HCV.
These data provide additional support to the hypothesis that HDACs are critical
for the antiviral actions of IFNa and suggest a role for theophylline, or other
inducers of HDACs, in the management of HCV by the current treatment
regimen.
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Figure 14: Theophylline enhances IFNa-mediated PKR mRNA induction and
anti-HCVactivity and boosts HDAC1 mRNA induction in human hepatoma
cells. Theophylline pretreatment enhanced IFNa-stimulated PKR mRNA
induction and suppression of HCV RNA. Theophylline alone significantly induced
PKR and HDAC1 mRNA induction and suppressed HCV RNA. Error bars
indicate SDM (N=3; a=

P~

0.05 vs UT, b=
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0.05 vs IFN).

Summary of data:
.:. Pharmacological inhibition of Class I HDACs showed that HDACs are
required:
o

for IFNa-mediated antiviral gene expression and anti-HCV activity

o

for retention of pSTAT1 in the nucleus

o

for STAT1 :HDAC1 association in the nucleus

o

to prevent acetylation of STAT1

.:. Studies with siRNA identified HDACs 1 and 3 as being critical for IFNamediated antiviral activity .

•:. Theophylline boosted HDAC1 mRNA induction and enhanced IFNamediated antiviral gene induction and anti-HCV activity.
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Cytoplasm

Figure 15: Schematic representation of the role of HDACs in IFNamediated anti-HCV gene expression in hepatocytes.
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IMPAIRED SAM METABOLISM AND INTERFERON·ALPHA SIGNALING

Impaired SAM metabolism decreases methylation potential in human
hepatoma cells.
SAM serves as the major methyl donor in transmethylation reactions and is
converted to SAH after transfer of its methyl group. SAH, a potent inhibitor of
methyltransferases, is rapidly broken down to homocysteine and adenosine by
the enzyme SAHH, which is critical for removal of SAH and maintaining the
SAM:SAH ratio (methylation potential). The reaction catalyzed by SAHH is
reversible and the equilibrium favors the formation of SAH, but rapid cellular
uptake of adenosine and homocysteine drives the reaction in the other direction 6 ,
14,47,80

(Fig. 2). We used the pharmacological SAHH inhibitors AD and DZA, as

well as equimolar amounts of adenosine plus homocysteine (AdenHcy), to
increase intracellular SAH and decrease methylation potential in human
hepatoma cells. Cells were treated with these SAM metabolism disruptors for 3
hours and deproteinized extracts were analyzed by HPLC. All the SAM
metabolism disruptors induced an increase in intracellular SAH and this
correlated to a decrease in SAM:SAH, or in methylation potential. These results
clearly showed that AD, DZA, and AdenHcy are useful tools for decreasing
methylation potential and supported the use of these SAM metabolism disruptors
for studying the effects of impaired transmethylation on IFNa-mediated anti-HCV
gene expression.
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Impaired SAM metabolism blocks IFNa-inducible antiviral gene expression
in human hepatoma cells.
Decreased methylation potential, due to increased SAH and impaired SAM
metabolism, has been documented in persons with chronic liver disease 5 , 6, 69.
To determine how impaired SAM metabolism affects IFNa anti-HCV signaling,
we used an Huh? cell line stably transfected with an HCV replicon (HCVR cells).
Preliminary experiments revealed that 1OU/mllFNa was sufficient to suppress
HCV RNA induction by 50% after 24 hours of exposure. To analyze the effects
of impaired SAM metabolism on the anti-HCV action of IFNa, HCVR cells were
pretreated with SAM metabolism disruptors for 3 hours prior to stimulation with
1OU/mllFNa for 24 hours. Cells treated with IFNa alone showed a 50%
suppression of HCV RNA, which was significantly reversed by pretreatment with
SAM metabolism disruptors. AD partially reversed the action of IFNa, resulting in
40% suppression of HCV, while AdenHcy and DZA completely blocked IFNamediated anti-HCV activity. Importantly, DZA and AdenHcy treatment alone led
to increased HCV RNA induction (Fig. 14). These data clearly show that
impaired SAM metabolism, induced by either SAHH inhibition or exogenous
AdenHcy supplementation, decreased the anti-HCV activity of IFNa. Importantly,
DZA and AdenHcy alone led to an increase in HCV RNA replication, which
suggest that the HCV promoter may be under methylation control.
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Figure 16: Impaired SAM metabolism inhibits IFHa anti-HCV activity in
human hepatoma cells. SAM metabolism disruptors (AdenHcy, AD, and DZA)
significantly reversed IFNa-mediated suppression of HCV RNA. AdenHcyand
DZA treatment alone enhanced HCV RNA induction. Error bars indicate SDM
(N=3; a= PS 0.05 vs UT, b= PS 0.05 vs IFN).

Next, we wanted to determine if the blockade of IFNa anti-HCV activity caused
by SAM metabolism disruptors would correlate with reduced induction of IFNastimulated antiviral genes PKR, OAS, and ISG15. IFNa led to marked induction
of all the antiviral genes, which was significantly reduced by pretreatment with
SAM metabolism disruptors. To confirm that these results were not an artifact of
using a transfected cell line, we conducted the same experiments in the parental
Huh? cell line. Similar to the results obtained in HCVR, pretreatment of Huh?
cells with SAM metabolism disruptors inhibited IFNa-mediated induction of PKR,
OAS, and ISG15 (Fig. 1?).

Taken together, these results clearly demonstrate
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the role of SAM metabolism for the anti-HCV action of IFNa in human hepatoma
cells.
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Figure 17: Impaired SAM metabolism inhibits IFNa-mediated antiviral gene
induction and anti-HCV activity in human hepatoma cells. SAM metabolism
disruptors (AdenHcy, AD, and DZA) significantly reduced IFNa-mediated antiviral
gene induction.

Error bars indicate SDM (N=3; a= p~ 0.05 vs UT, b=

vs IFN).

46

p~

0.05

Impaired SAM metabolism blocks IFNa-induced activation of the ISRE in
antiviral gene promoters.
Transcription of IFNa-stimulated antiviral genes is dependent on activation of the
ISRE found in their promoters. Based on our data showing that SAM metabolism
disruptors significantly inhibited IFNa-mediated antiviral gene induction and antiHCV activity, we hypothesized that impaired SAM metabolism may also block
activation of the ISRE. Human hepatoma cells were transiently transfected in a
large batch with an ISRE-Iuciferase reporter construct. Following transfection,
cells were reseeded into 24-well plates and treated for 6 hours with IFNa alone,
or stimulated with IFNa after 3 hour pretreatment with SAM metabolism
disruptors. As expected, treatment with IFNa alone led to robust activation of the
ISRE-Iuciferase reporter and pretreatment with SAM metabolism disruptors led to
almost a complete attenuation of activation (Fig. 18). Previously data from our
lab showed that treatment with AD inhibited binding of transcription factors to the
ISRE in electrophoretic mobility shift assays. Taken together, these data support
the idea that maintaining proper SAM metabolism is critical for activation of IFNastimulated antiviral genes via ISRE.
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Figure 18: Impaired SAM metabolism inhibits IFHa-mediated activation of
the ISRE in human hepatoma cells. SAM metabolism disruptors (AdenHcy,
AD, and DZA) blocked IFNa-stimulated ISRE activation in Huh 7 cells. SAM
metabolism disruptors did not activate the ISRE.

Impaired SAM metabolism inhibits IFHa-mediated pSTAT1, OAS, and PKR
protein expression in human hepatoma cells.
IFNa exerts its antiviral action by activating the JAKISTAT signaling cascade so it
was important to determine if impaired SAM metabolism alters critical steps in
the signaling pathway. IFNa binds cell surface receptors leading to activation of
JAKISTAT signaling. Of particular importance in this cascade is phosphorylation
of STAT proteins on tyrosine residue 701 (Y701), which causes them to dimerize
and translocate to the nucleus where they associate with IRF9 to form the ISGF3
transcription complex that binds the ISRE leading to antiviral gene induction.
This pathway is regulated in several ways including dephosphorylation of STATs
by phosphatases, and binding of STATs to their negative regulator protein
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inhibitor of activated STATs (PIAS)73, 120. We performed western blots using
whole cell Iysates from human hepatoma cells and analyzed the effects of DZA
on IFNa-stimulated STAT1 Y701 phosphorylation. Cells treated with IFNa alone
showed robust STAT1 Y701 phosphorylation, which was reduced in cells that
received DZA prior to stimulation with IFNa (Fig. 19). To determine if DZA
inhibits STAT1 Y701 phosphorylation by inducing phosphatases, we treated cells
in the presence of sodium vanadate (Na3V04) and sodium flouride (NaF), which
inhibit tyrosine and serine/threonine phosphatases, respectivell 4. Interestingly,
STAT1 Y701 phosphorylation was rescued with NaF but not Na3V04, thus
suggesting that impaired SAM metabolism inhibits IFNa-mediated anti-HCV
signaling by interfering with STAT1 serine phosphorylation. Several reports have
indicated that phosphorylation of STAT1 on S727 is required for the optimal
transcriptional activity of STAT1 106, 121, 127. To determine if STAT1 S727
phosphorylation was affected, the membrane was stripped and reprobed with
primary antibody against pSTAT1 S727. As seen in Figure 19, cells treated with
DZA showed a marked decrease in pSTAT1 S727 when compared to cells
treated with IFNa alone. To ensure that our results were not due to uneven
loading of our protein samples, we also probed the blot with a total STAT1
antibody. Total STAT1 was equal in all lanes confirming that DZA blocks IFNamediated phosphorylation of STAT1 on both its Y701 and S727 residues.

RT-PCR data revealed that impaired SAM metabolism downregulated IFNastimulated antiviral gene induction. We treated human hepatoma cells for 24
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hours with IFNa alone or after 3 hour pretreatment with DZA. Whole cell protein
Iysates were collected and analyzed by Western blot for antiviral PKR and OAS
protein expression . IFNa treatment induced expression of both PKR and

~AS.

Pretreatment with DZA inhibited IFNa-stimulated OAS protein expression and
slightly reduced PKR protein expression. j3-actin antibody was used to confirm
equal loading between samples (Fig. 19). Taken together, these data show that
impaired transmethylation affects IFNa-mediated anti-HCV action by disrupting
critical steps in the JAKISTAT signaling cascade, which subsequently inhibits
antiviral protein expression.
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Figure 19: Impaired SAM metabolism inhibits IFNa-mediated pSTAT1, OAS,
and PKR protein expression in human hepatoma cells. DZA inhibited IFNamediated STAT1 phosphorylation and expression ofthe antiviral proteins, PKR
and OAS, in whole cell protein Iysates from Huh 7 cells. Total STAT1 and f3-actin
antibodies were used to confirm equal loading of proteins between samples.
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Impaired SAM metabolism increases STA T1 :PIAS1, which correlates with
decreased STA T1 :PRMT1 in the nucleus of human hepatoma cel/s.
One mechanism by which JAKISTAT signaling is negatively regulated is through
association of STAT1 with PIAS1 in the nucleus of cells. Importantly, formation
of the STAT1 :PIAS1 complex is prevented by methylation of STAT1, which is
catalyzed by association of STAT1 with the methyltransferase PRMT1 73 , 85.
Impaired SAM metabolism leads to an increase in intracellular SAH that inhibits
methyltransferase reactions. To analyze the affects of impaired SAM metabolism
on STAT1 :PIAS1, human hepatoma cells were treated with IFNa for 30 minutes
alone or after 3 hour pretreatment with DZA or AD. Nuclear protein Iysates were
collected and equal amounts of protein were immunoprecipitated with STAT1
antibody. The immunocomplexes were analyzed by Western blot for association
with PIAS1 and PRMT1. As seen in Figure 20, pretreatment with DZA or AD
blocked IFNa-induced formation of STAT1 :PRMT1 complex, which correlated
with an increase in STAT1 :PIAS1. These data support a role for SAM
metabolism in regulation of IFNa-HCV signaling by controlling negative inhibition
of the JAKISTAT signaling pathway.
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Figure 20: Impaired SAM metabolism decreases STA T1 :PRMT1 and
increases STA T1 :PIAS1 association in the nucleus of human hepatoma
cells. Immunoprecipitation of Huh 7 nuclear protein Iysates with STAT1 antibody
revealed an IFNa-stimulated STAT1:PRMT1 complex that is inhibited by DZA
(top). IFNa reduced STAT1:PIAS1 association, which was reversed by
pretreatment with AD (bottom).

SAM supplementation boosts IFNa-mediated antiviral gene induction and
anti-HCV activity in human hepatoma cells.
Our data clearly show that impaired SAM metabolism downregulates IFNa
antiviral gene induction and anti-HCV activity and suggest that SAM plays a
critical role in managing HCV by the current treatment regimen. Next, we wanted
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to determine if SAM supplementation would enhance the anti-HCV actions of
IFNa. HCVR cells were treated for 24 hours with 1mM SAM prior to stimulation
with 10U/mllFNa for 24 hours. Total RNA was extracted and used to analyze
mRNA levels of PKR, OAS, and ISG15, as well as HCV RNA levels, by RT-PCR.
IFNa treatment alone led to significant activation of the antiviral genes and SAM
pretreatment caused at least a 2-fold enhancement of induction of each gene.
Interestingly, SAM treatment alone cause significant induction of the antiviral
genes. SAM pretreatment also enhanced the anti-HCV action of IFNa resulting
in 75% suppression compared to 50% suppression seen in cells treated with
IFNa alone. Importantly, SAM itself suppressed HCV RNA by 23% (Fig. 21).
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Figure 21: SAM boosts IFHa-mediated antiviral gene induction and antiHCV activity in human hepatoma cells. SAM enhanced IFNa-mediated PKR,
OAS, and ISG15 mRNA induction and suppression of HCV RNA. SAM treatment
alone significantly induced antiviral mRNA induction and suppressed HCV.
Error bars indicate SDM (N=3; a=
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0.05 vs UT, b=

53

p~

0.05 vs IFN).

Next, we wanted to determine if SAM supplementation would restore the antiHCV action of IFNa that was inhibited by SAM metabolism disruptors. HCVR
cells were treated with DZA for 3 hours, then SAM for 24 hours, prior to
stimulation with IFNa for 24 hours. HCV RNA was suppressed by 45% in cells
that received IFNa and DZA blocked this effect, which brought HCV RNA levels
back to baseline. Importantly, SAM supplementation restored the anti-HCV
activity of IFNa, resulting in 49% suppression of HCV RNA (Fig. 22). Taken
together, these data indicate a role for SAM supplementation, by enhancing IFNa
antiviral activity, in management of HCV.
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Figure 22: SAM restores IFNa-mediated anti-HCV activity that was blocked
by inhibition of SAM metabolism. DZA reversed the anti-HCV action of IFNa
in HCVR cells and this effect was blocked by SAM. Error bars indicate SDM
(N=3; a=
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0.05 vs UT, b=
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0.05 vs IFN).
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Impaired SAM metabolism downregulates HDAC gene induction in human
hepatoma cel/s.
Our previous studies using HDACi and siRNA demonstrated the critical need for
HDAC1 and HDAC3 in IFNa-mediated anti-HCV activity. To expand on these
findings, we wanted to determine if impaired SAM metabolism modified HDAC
gene expression. Human hepatoma cells were treated with SAM metabolism
disrupters for 3 hours then stimulated with IFNa for 2 hours. Total RNA was
extracted and used to analyze induction of class I HDACs (1,2,3, and 8) and
class II HDACs (4,5,6, 7a, 9, and 10) by RT-PCR. As seen in Figures 23 and
24, none of the SAM metabolism disruptors induced significant changes in
HDAC3 or HDAC5. HDAC1, HDAC6, and HDAC8 gene inductions were
significantly reduced in cells that received AD. Cells treated with AdenHcy or
DZA showed reduced induction of HDAC2 and HDAC9. Importantly, all of the
SAM metabolism disruptors caused significant reduction in HDAC4, HDAC7, and
HDAC10 gene induction (Fig. 24). These results support our previous data
showing the requirement of HDACs in IFNa anti-HCV activity. The differential
effects of the SAM metabolism disruptors on HDACs 1, 2, 6, 8, and 9 are
possibly due to their specific chemical properties as opposed to being an effect of
impaired SAM metabolism. Induction of HDACs 4,7, and 10 was suppressed by
all SAM metabolism disruptors indicating these HDACs may playa critical role in
maintaining proper SAM metabolism and suggest the need for further studies in
this area.
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Figure 24: Effect of impaired SAM metabolism on class II HDAC gene
induction in human hepatoma cells. Each of the SAM metabolism disruptors
(AdenHcy, AD, and DZA) significantly reduced induction of HDAC4, HDAC7, and
HDAC10 mRNA. Error bars indicate SDM (N=3; a=

vs IFN).

58

p~

0.05 vs UT, b=

p~

0.05

Summary of data:
.:. SAM metabolism disruptors blocked IFNa-mediated antiviral gene
induction and suppression of HCV
o

AdenHcyand DZA boosted HCV RNA

.:. SAM metabolism disruptors blocked IFNa-stimulated STAT1
phosphorylation
o

Increased STAT1 :PIAS1 association

o

Decreased STAT1 :PRMT1 association

.:. SAM metabolism disruptors inhibited HDAC4, HDAC7, and HDAC10
mRNA induction

.:. SAM supplementation boosted IFNa-mediated antiviral gene induction and
suppression of HCV
o

SAM alone suppressed HCV RNA

.:. SAM supplementation reversed the inhibitory action of DZA on the antiHCV action of IFNa
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ACROLEIN AND INTERFERON-ALPHA SIGNALING

Acrolein inhibits IFHa-mediated antiviral gene expression and anti-HCV
activity in human hepatoma cells.
HCV disease progression and response to IFNa therapy depend on a variety of
factors including obesity, oxidative stress, and external factors such as smoking,
and exposure to environmental pollutants 35 , 117, 122. Acrolein is a component of
cigarette smoke, as well as an environmental pollutant, and can also be formed
endogenously through the process of lipid peroxidation 54 , 56, 65, 90. We analyzed
the effects of acrolein exposure on IFNa-mediated anti-HCV gene expression in
human hepatoma cells. Cells were treated for 30 minutes with acrolein prior to
stimulation with IFNa for 2 hours and total RNA was extracted and analyzed by
RT-PCR. IFNa treatment caused robust induction of the antiviral genes PKR,
OAS, and ISG15, which was significantly inhibited by pretreatment with acrolein
(Fig. 25). Acrolein treatment alone significantly reduced PKR mRNA induction
compared to UT cells. To determine if the reduction in antiviral gene
transcription correlated with reduced anti-HCV activity of IFNa, HCVR cells were
treated with acrolein for 30 minutes prior to stimulation with IFNa for 24 hours.
IFNa alone suppressed HCV by 35% and pretreatment with acrolein dosedependently reversed the anti-HCV action. Interestingly, acrolein treatment
alone significantly increased HCV RNA (Fig. 25). These data suggest that
exposure to acrolein may contribute to HCV disease progression and poor
response to therapy.
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Figure 25: Acrolein inhibits IFNa-mediated antiviral gene expression and
anti-HCV activity in human hepatoma cells. Acrolein dose-dependently
inhibited IFNa-mediated antiviral mRNA induction and suppression of HCV RNA.
Acrolein suppressed PKR mRNA and induced HCV RNA. Error bars indicate
SDM (N=3; a=
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0.05 vs UT, b=
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0.05 vs IFN).
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Acrolein suppresses class I HDAC activity and gene expression in human
hepatoma cells.
Based on our previous studies showing the critical role of class I HDACs in IFNamediated anti-HCV signaling, we wanted to determine if acrolein modified HDAC
activity and/or gene transcription. Nuclear protein Iysates were extracted from
human hepatoma cells treated for 3 hours with increasing doses of acrolein.
HDAC activity was measured using the Epigenase HDAC Activity Direct Assay
Kit as per the manufacturer's protocol and normalized against protein
concentration. HDAC activity was decreased in all samples and correlated with
acrolein dose (Fig. 26).
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Figure 26: Acrolein decreases HDAC activity in human hepatoma cells.
Acrolein reduced HDAC activity in nuclear Iysates from Huh 7 cells. Data was
normalized against protein concentration. Representative of 2 independent
experiments.
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In order to see if the decrease in HDAC activity correlated with reduced class I
HDAC gene expression, human hepatoma cells were treated for 3 hours with
acrolein and total RNA was extracted and analyzed by RT-PCR. As seen in
Figure 27, acrolein significantly reduced transcription of all class I HDACs.
Taken together, these results suggest that one mechanism by which acrolein
inhibits IFNa anti-HCV activity is through inhibition of class I HDACs, which are
required for IFNa-mediated antiviral signaling.
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Figure 27: Acrolein decreases class I HDAC gene induction in human
hepatoma cel/s. Acrolein significantly suppressed HDAC1, HDAC2, HDAC3,
and HDAC8 mRNA induction in Huh? cells. Error bars indicate SDM (N=3; a=
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Summary of data:
.:. Acrolein blocked IFNa-mediated antiviral gene induction and suppression
ofHCV
o

Acrolein boosted HCV RNA

.:. Acrolein suppressed class I HDAC activity and gene expression
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CHAPTER IV
DISCUSSION

HCV infection remains one of the leading causes of acute hepatitis and chronic
liver disease in the US. Most people infected with HCV will develop chronic
infections and approximately 50% of persons with HCV do not respond to the
traditionallFNa plus ribavirin therapy. Poor response to therapy depends on a
variety of factors including viral genotype, viral load, obesity, alcohol
consumption, smoking, and exposure to environmental pollutants 5, 35.
Additionally, HCV invokes several countermeasures that inhibit the antiviral
actions of IFNa including induction of PP2A, SOCS-1, SOC-3, and oxidative
stress 11,52,69,104. Despite ongoing research on HCV, the molecular mechanisms,
which include both host- and virus-specific factors, involved in resistance to
therapy are not completely understood. These studies were performed to
elucidate the mechanism(s) contributing to resistance to therapy and poor
treatment outcomes in the management of HCV.

HDACs were historically identified based on their ability to remove acetyl groups
from K residues on histone tails. The removal of these acetyl groups removes
the negative charges that repel DNA, leading to chromatin condensation and
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reduced transcription due to inaccessibility of transcription machinery to gene
promoters. In more recent years, there has been a growing body of evidence
showing that HDACs also exert action on non-histone proteins, in particular
transcription factors, leading to altered gene expression 41 , 87, 124. The possible
role of HDACs in modifying gene expression due to transcription factor
modifications must be considered in inducible gene systems.

Taking into account the historical role of HDACs in downregulating gene
expression due to chromatin condensation, we expected to see enhanced
antiviral gene expression and suppression of HCV RNA when human hepatoma
cells were treated with HDAC inhibitors prior to stimulation with IFNa. We
instead observed a decrease in antiviral gene expression, which correlated with
inactivation of the ISRE, and partial reversal of the anti-HCV action of IFNa. The
anti-HCV properties of IFNa are mediated through activation of the JAKISTAT
signaling cascade. Critical steps in this pathway include phosphorylation of
STAT1 on Y701 and S727, which are required for nuclear translocation and
optimal transcriptional activity, respectivell 8 , 100, 121, 127. We initially performed
Western blot analysis on whole cell protein Iysates from appropriately treated
cells but did not observe a change in STAT1 phosphorylation in cells that
received HDACi prior to stimulation with IFNa. However, when we analyzed
STAT1 phosphorylation in cytoplasmic and nuclear protein Iysates, we noticed a
clear difference in the partitioning of pSTAT1; HDACi pretreated cells showed
cytoplasmic accumulation compared to nuclear accumulation in cells stimulated
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only with IFNa. STAT signaling can be inhibited by acetylation of STAT1 in the
nucleus, which leads to its translocation out of the nucleus and reduced gene
transcription. Acetylation of STAT1 in the nucleus is mediated through binding
with the HAT protein CBp 58 , 61, 62. Our data showed that IFNa induced formation
of a STAT1 :HDAC1 complex in the nucleus and HDACi pretreatment inhibited
formation of this complex, which correlated to an increase in STAT1 acetylation.
It is reasonable to speculate that, in addition to recruiting RNA polymerase to
antiviral gene promoters, HDACs playa critical role in regulating IFNa-mediated
anti-HCV gene expression by aSSOCiating with STAT1 to circumvent CBPinduced acetylation and retain activated STATs in the nucleus.

The HDAC inhibitors used in our experiments, TSA and SBHA, are class I HDAC
inhibitors and decrease the activity of HDACs 1, 2, 3, and 8. Using siRNA, we
identified HDACs 1 and 3 as being critical for IFNa-mediated anti-HCV gene
expression. Silencing of HDAC1 or HDAC3 led to a partial, yet significant,
decrease in IFNa-stimulated anti-HCV gene expression and also inhibited
formation of the STAT1 :HDAC1 complex. Taken together, these results suggest:
1) there is redundancy between the HDACs that allows one to compensate when
the other is silenced; and 2) HDAC3 plays a role in keeping STATs deacetylated
and retained in the nucleus. The role of HDAC3 in keeping STATs deacetylated
is supported by other data from our lab showing formation of a STAT2:HDAC3
complex in nuclear Iysates from IFNa stimulated cells. Additionally, we observed
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HDACi-induced retention of pSTAT2 in cytoplasmic Iysates of IFNa-stimulated
cells.

When compared to pretreatment with HDACi, silencing of HDAC1 or HDAC3 by
siRNA suppressed IFNa-mediated antiviral gene induction to a much lesser
degree. The differences between the results obtained with HDACi versus siRNA
are likely due to the fact that TSA and SBHA block activity of all class I HDACs,
whereas siRNA blocks induction and expression of the respective HDAC genes.
It is reasonable to speculate that double transfection with both siHDAC1 and
siHDAC3 may reduce IFNa-stimulated antiviral gene induction to levels similar to
those obtained with HDACi pretreatment. Alternatively, there may be
redundancy between the HDACs that causes one to be induced when the other
is silenced. Further studies are needed to further elucidate the roles of HDAC1
and HDAC3 in IFNa-mediated anti-HCV gene expression.

Recent reports have shown that theophylline induces HDAC activity to modify
gene expression 22 , 53. To further elucidate the role of HDACs in IFNa-mediated
anti-HCV signaling, we used theophylline to boost HDAC gene expression and
analyzed its effects on antiviral gene induction. We observed a theophyllineinduced increase in HDAC1 mRNA induction, which correlated with enhanced
IFNa-mediated PKR mRNA induction and suppression of HCV RNA.
Importantly, theophylline alone induced PKR mRNA and suppressed HCV RNA
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induction. These data are consistent with a recently published report showing
that theophylline inhibits replication of hepatitis B virus 128.

The theophylline doses used in this study were used for proof-of-concept and are
not physiologically relevant. However, theophylline is known to boost HDAC
activity and is a metabolite of caffeine. Freedman et al have reported that HCV
patients who consume coffee have better response to the IFNa plus ribavirin
therapy. It is possible that the enhanced antiviral response is partially due to the
caffeine found in coffee.

SAM is of pivotal importance in cellular metabolism serving as the major donor of
methyl groups in transmethylation and transsulfuration reactions. Elevations in
intracellular SAH will disrupt the SAM metabolism pathway and impaired SAM
metabolism is a well documented feature of chronic liver injurl' 75, 77. Our data
clearly show that disrupting SAM metabolism, by SAHH inhibition or exogenous
supplementation of adenosine and homocysteine, dramatically reduced IFNastimulated antiviral gene induction, which correlated with impaired activation of
the ISRE, and reversed the anti-HCV action of IFNa. Western blot analysis
revealed a decrease in both pSTAT1 Y701 and pSTAT1 S727 in whole cell protein
Iysates from cells treated with SAM metabolism disruptors prior to stimulation
with IFNa. Negative regulation of JAKISTAT signaling occurs when STAT1 is
bound to PIAS1, an association that is controlled by PRMT1-induced methylation
of STAT1. Immunoprecipitation of nuclear Iysates with STAT1 antibody revealed
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IFNa-induced formation of a STAT1 :PRMT1 complex that was inhibited by
pretreatment with SAM metabolism disruptors. Importantly, SAM metabolism
disruptors caused an increase in the STAT1 :PIAS1 complex compared to cells
treated with IFNa alone. Previous data from our lab also revealed methylation of
STAT1 that was inhibited by treatment with SAM metabolism disruptors These
data suggest a critical role for SAM metabolism in IFNa-mediated anti-HCV gene
expression.

Exogenous supplementation of SAM significantly enhanced in IFNa-mediated
anti-HCV gene expression and suppression of HCV RNA. Importantly, SAM
treatment alone significantly induced PKR, OAS, and ISG15 mRNA induction and
suppressed HCV RNA. Previous data from our lab also revealed that SAM
supplementation increased methylation of STAT1 , which correlated with a
decrease in STAT1 :PIAS1. Finally, SAM supplementation reversed the inhibitory
effects of DZA on IFNa-mediated antiviral gene expression and anti-HCV activity.
These data suggest a role for SAM as adjunct therapy in management of HCV.
A recently published report by Feld et a/ indeed showed that SAM improved early
response in HCV patients on IFNa plus ribavirin therapy who previously did not
respond to the traditional anti-HCV therapl1. Additionally, our data showing
suppression of HCV by SAM treatment alone suggests that the HCV promoter
might be controlled by methylation and points to the need for future studies in this
area.
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HDACs are required for IFNa-mediated antiviral gene expression and we
specifically identified HDAC1 and HDAC3 as being critical for IFNa anti-HCV
activity. Interestingly, none of the SAM metabolism disruptors affected induction
of HDAC1 or HDAC3. Next, we analyzed the effects of these disruptors on class
II HDAC inductions. HDAC4, HDAC7, and HDAC10 were significantly
downregulated in response to each SAM metabolism disruptor used in this study
suggesting that these HDACs play an important role in IFNa antiviral signaling as
well as SAM metabolism and maintaining the SAM/SAH ratio.

Future studies

are needed to determine if these HDACs playa role in regulating STATs and/or
other transcription factors required for IFNa-mediated anti-HCV gene expression.
Additionally, these HDACs may modify the epigenetic landscape, including
alterations in chromatin structure, at IFNa antiviral gene promoters. Finally, it is
possible that HDACs 4,7, and 10 affect enzymes in the SAM metabolism
pathway, such as MAT1 or SAHH enzymes, thus regulating SAM formation
and/or utilization.

Acrolein is a hepatotoxic aldehyde that is a component of smoke, as well as a
product and inducer of oxidative stress, and exposure to acrolein might correlate
to poor response to IFNa anti-HCV therapl4. In fact, smokers have a lower
response to IFNa anti-HCV therapy than nonsmokers, which correlates with an
increase in liver fibrosis 29 . We used sublethal doses of acrolein, which were also
within the physiological range, to show that acrolein downregulated IFNamediated antiviral gene expression and reversed the anti-HCV action of IFNa.
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Importantly, acrolein alone led to an increase in HCV RNA suggesting that
exposure to acrolein enhances disease progression and contributes to poor
response to therapy. Acrolein also significantly reduced HDAC activity and
induction of the class I HDACs: HDAC1, HDAC2, HDAC3, and HDAC8. Previous
data from our lab also showed that acrolein impairs IFNa-induced JAKISTAT
signaling by inhibiting phosphorylation of STAT1 and STAT2, which correlated to
an increase in serine and tyrosine phosphatase activitl4. These data clearly
show a role for acrolein in reducing IFNa-mediated antiviral gene expression and
enhancing the progression of HCV.
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CHAPTER V
CONCLUSIONS

The data presented herein show that HDACs and SAM play critical roles in
regulating IFNa antiviral signaling and anti-HCV activity. We have presented
convincing evidence that HDACs modify signaling by keeping the transcription
factor STAT1 deacetylated, which increases its retention in the nucleus. We also
show that HDACs are required for STAT binding to antiviral gene promoters,
however, it is reasonable to assume that HDACs also modify local chromatin
structure at IFNa-stimulated anti-HCV gene promoters to alter gene transcription.
The critical role of HDACs in IFNa anti-HCV signaling is further supported by the
fact that SAM metabolism disruptors and acrolein all modified the activity and/or
induction of several HDACs.

SAM metabolism is required for IFNa-mediated anti-HCV gene expression and to
prevent association between STAT1 and its negative regulator PIAS1. SAM
metabolism disruptors significantly reduced induction of HDAC4, HDAC7, and
HDAC10 mRNAs. These HDACs may play critical roles in maintaining SAM
metabolism and SAM/SAH ratio in hepatocytes. Alternatively, these HDACs may
modify other transcription factors in the IFNa anti-HCV signaling pathway.
Finally, SAM treatment alone suppressed HCV RNA suggesting that the HCV
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genome may be under methylation control and points to the need for future
studies.

Acrolein exposure significantly reduced IFNa-mediated antiviral gene induction
and anti-HCV activity. Acrolein suppressed the activity and induction of all class I
HDACs: HDAC1, HDAC2, HDAC3, and HDAC8. Importantly, acrolein treatment
itself induced HCV RNA induction. Acrolein induces oxidative stress, which
correlates with HCV disease progression and poor treatment outcomes,
however, it is possible that acrolein-induced inhibition of HDAC activity and/or
expression also contributes to poor IFNa anti-HCV response.

Overall conclusion:
We have elucidated the critical roles of HDACs and SAM in IFNa signaling and
epigenetic regulation of anti-HCV gene expression. SAM and/or HDAC inducers
may be useful as adjunct therapy to improve response to the IFNa anti-HCV
treatment regimen.
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